RT Journal Article
SR Electronic
T1 Risk of second primary malignancies (SPM) following radioactive I-131 (RAI) therapy in patients with differentiated thyroid cancer (DTC)
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1084
OP 1084
VO 51
IS supplement 2
A1 Ansari, Aiysha
A1 Kulkarni, Kanchan
A1 Van Nostrand, Douglas
A1 Khorjekar, Gauri
A1 Garcia, Carlos
YR 2010
UL http://jnm.snmjournals.org/content/51/supplement_2/1084.abstract
AB 1084 Learning Objectives 1. To understand the risk and incidence of second primary malignancy (SPM) following RAI therapy in patients with differentiated thyroid cancer. 2. List all the organ systems that have been reported to have an association between RAI therapy and occurrence of SPMs. 3. To review the risk factors associated with occurrence of SPMs following RAI therapy. The increased incidence of second primary malignancy in patients with DTC following RAI is controversial and is reported to be elevated according to some studies. Extensive literature search was performed regarding this subject. The relationship between RAI and various SPMs including that of the salivary glands, bone, soft tissue, breast, colorectal, leukemia, prostate and hematological malignancies reported in various publications will be presented. The data from key retrospective studies addressing the incidence of these tumors will be presented. The exhibit will provide a comprehensive review of the key reports, numerous risk factors and possible mechanisms of increased risk of SPM within these reports. With the information presented, the nuclear medicine physicians and endocrinologists will be better informed about the risk of development of SPM in patients with differentiated thyroid cancer and possibly address the concern of their patients regarding the riskRisk of Second Primary Malignancy Following RAI TherapyRR: Relative Risk, SIR: Standardized Incidence Ratio, CI: Confidence Interval, PV: P Value. RAI: Radioactive Iodine, NR: Not Reported.